

---

# Exploring the Consequence: Sexual Brokenness and Barrenness as Late Impacts of Malignant Growth Treatment

Department of Behavioral Science, Unit 1330, University of Texas MD Anderson Cancer Center, Houston, USA

Surviving cancer is a testament to resilience and strength, marking a significant milestone in one's life. However, the journey towards recovery extends beyond the triumphant moment of remission. For many cancer survivors, the aftermath of treatment brings forth a range of long-term challenges, with sexual dysfunction and infertility emerging as impactful and often overlooked late effects [1].

The toll of cancer treatment on the body and mind can be profound, and while the focus during treatment is primarily on eradicating the disease, the lasting consequences on sexual health and fertility demand our attention. This article delves into the intricate interplay between cancer treatments and their potential ramifications on sexual well-being and reproductive capacity. By understanding the complexities of these late effects, we can pave the way for more comprehensive survivorship care, addressing not only the physical aspects but also the emotional and relational dimensions of life after cancer [2].

Introduction and Objectives:

1. **Objective:** To explore the late effects of cancer treatment on sexual health and fertility.

Beyond the physical toll exacted by cancer treatments such as chemotherapy, radiation, and surgery lies a realm seldom openly discussed—sexual dysfunction. The aftermath of these treatments can introduce a myriad of changes, from alterations in blood flow and hormonal imbalances to the potential nerve damage incurred during surgical interventions [3]. The intersection of these physical alterations with the psychological toll of a cancer diagnosis creates a complex tapestry where intimacy becomes entwined with issues of desire, arousal, and overall satisfaction.

It is imperative to recognize that the psychological impact of cancer extends beyond the immediate treatment phase. Coping with the existential weight of a cancer diagnosis and navigating the rigors of treatment can give rise to anxiety, depression, and profound shifts in body image [4]. As survivors confront these psychological challenges, they find themselves contending not only with the scars left by the disease but also with the echoes of its impact on their emotional and relational well-being.

2.

---

Lisa Schover, Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, USA, E-mail: [lisa@anderson.org](mailto:lisa@anderson.org)

01-Nov-2023, Manuscript No. acp-23-121843; 04-Nov-2023, PreQC No. acp-23-121843(PQ); 18-Nov-2023, QC No. acp-23-121843; 25-Nov-2023, Manuscript No. acp-23-121843(R); 30-Nov-2023; DOI: 10.4172/2472-0429.1000198

Schover L (2023) Exploring the Consequence: Sexual Brokenness and Barrenness as Late Impacts of Malignant Growth Treatment *Adv Cancer Prev* 7: 198.

© 2023 Schover L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

- 
4. McKinney SM, Sieniek M, Godbole V, Godwin J (2020). International evaluation of an AI system for breast cancer screening. *Nature* 577:89-94.
  5. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, et al. (1986) Lung cancer screening: the Mayo program. *J Occup Med US* 28:746-750.
  6. Stroissnigg FH, Ling YY, Zhao J (2017) novel class of senolytics. *Nat Commun EU* 8: 1-14.
  7. Fidalgo JAP, Roda D, Roselló S (2009) Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. *Clin Transl Oncol EU* 11:787-798.
  8. Folkman J (2003) Angiogenesis inhibitors: a new class of drugs. *Cancer Biol Ther US* 2:126-132.
  9. Sano M (2018) A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol EU* 71: 471-476.
  10. Sacchi S, Rosini E, Pollegioni L, Gianluca M (2013) D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. *Curr Pharm Des UAE* 19:2499-2511.